Canon Medical’s new Alphenix / Evolve Edition Angiography system, which was introduced in Europe in August 2023, has opened new windows of opportunity for Interventional Cardiologists. Unique Deep Learning technology with real-time application enables users of the Alphenix / Evolve Edition to enhance imaging and reduce the time and radiation dose required for routine and complex Interventional Cardiology procedures, such as Percutaneous Coronary Intervention (PCI) and Structural Heart Disease (SHD) treatments. The results are increased success in these intricate procedures and improved safety for clinicians and patients.
Imaging plays a crucial role in PCI and SHD interventions, from preprocedural evaluation and device size selection to treatment and follow-up. With the number of patients requiring these interventions growing rapidly on a global level, Canon Medical’s Alphenix / Evolve Edition Angiography System supports these complex procedures and enables clinicians to advance further with them than ever before.
“Interventional Cardiology departments are faced with growing clinical demands, financial pressures, and the need for improved efficiency, as the number and complexity of cases increase,” remarked Kunitoshi Matsumoto, Global General Manager of Canon Medical’s Vascular Systems Division. “To meet these challenges, Canon Medical has introduced the Alphenix / Evolve Edition.”
Technology that supports progress
The new Angiography system features Canon Medical’s most advanced Deep Learning technology, powered by Altivity* - αEvolve Imaging – which includes a whole new suite of AI-technologies developed to provide instantaneous, real-time assistance for key diagnostic and therapeutic decisions without interrupting workflow. αEvolve Imaging utilizes Deep Learning based noise reduction and multi-frequency processing to provide cleaner, sharper, more defined images. Its complex algorithm enables outstandingly clear fluoroscopic imaging, which can deliver a two times higher contrast-to-noise ratio compared to conventional image processing.
αEvolve Imaging has been developed by Canon Medical and tested in several leading centers of healthcare expertise, including Kumamoto University Hospital (Japan).
“We have rigorously tested our new AI technologies in both development and clinical phases and are extremely confident that they will have a big impact on clinical success in Interventional Cardiology,” said Kunitoshi Matsumoto.
Canon Medical’s Altivity
Introducing Altivity, our bold new approach to AI innovation that uses smart technologies to make a whole new level of quality, insight and value across the entire care pathway possible. Designed specially to address the growing complexities of interventional cardiology we developed Evolve Technology. Leveraging Artificial Intelligence, Evolve provides innovative solutions to support high quality, safe and efficient diagnosis and treatment while improving the experience for patients and healthcare workers.